AU2002247826A1 - Specific binding members - Google Patents

Specific binding members

Info

Publication number
AU2002247826A1
AU2002247826A1 AU2002247826A AU2002247826A AU2002247826A1 AU 2002247826 A1 AU2002247826 A1 AU 2002247826A1 AU 2002247826 A AU2002247826 A AU 2002247826A AU 2002247826 A AU2002247826 A AU 2002247826A AU 2002247826 A1 AU2002247826 A1 AU 2002247826A1
Authority
AU
Australia
Prior art keywords
specific binding
binding members
members
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002247826A
Inventor
Sanjeev Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London University College
Original Assignee
London University College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US27524101P priority Critical
Priority to US60/275,241 priority
Application filed by London University College filed Critical London University College
Priority to PCT/GB2002/001141 priority patent/WO2002072635A2/en
Publication of AU2002247826A1 publication Critical patent/AU2002247826A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
AU2002247826A 2001-03-13 2002-03-13 Specific binding members Abandoned AU2002247826A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US27524101P true 2001-03-13 2001-03-13
US60/275,241 2001-03-13
PCT/GB2002/001141 WO2002072635A2 (en) 2001-03-13 2002-03-13 Specific binding members

Publications (1)

Publication Number Publication Date
AU2002247826A1 true AU2002247826A1 (en) 2002-09-24

Family

ID=23051444

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002247826A Abandoned AU2002247826A1 (en) 2001-03-13 2002-03-13 Specific binding members

Country Status (2)

Country Link
AU (1) AU2002247826A1 (en)
WO (1) WO2002072635A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3097121T3 (en) 2014-01-24 2019-04-15 Dana Farber Cancer Inst Inc Antibody molecules against PD-1 and uses thereof
KR20160134668A (en) 2014-03-14 2016-11-23 노파르티스 아게 Antibody molecules to lag-3 and uses thereof
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
JP2017520575A (en) 2014-07-01 2017-07-27 ファイザー・インク Bispecific heterodimeric diabodies and use thereof
JP2017527271A (en) 2014-07-21 2017-09-21 ノバルティス アーゲー Treatment of cancer using human anti bcma chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US20170211055A1 (en) 2014-07-21 2017-07-27 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
AU2015317608A1 (en) 2014-09-17 2017-04-06 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
AU2015333687A1 (en) 2014-10-14 2017-04-27 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
RU2017134652A (en) 2015-04-08 2019-04-09 Новартис Аг Cd20 therapy, CD22 therapy, and combination therapy with cells expressing the chimeric antigen receptor (car) k cd19
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3317301A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
BR112018012138A2 (en) 2015-12-17 2018-12-04 Novartis Ag antibody molecules for PD-1 and uses thereof
AU2016369623A1 (en) 2015-12-17 2018-06-28 Novartis Ag Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
EP3405492A1 (en) 2016-01-21 2018-11-28 Novartis AG Multispecific molecules targeting cll-1
KR20180118175A (en) 2016-03-04 2018-10-30 노파르티스 아게 Cells expressing multiple chimeric antigen receptor (CAR) molecules and their uses
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
SG11201809041TA (en) 2016-04-15 2018-11-29 Novartis Ag Compositions and methods for selective protein expression
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP3491016A1 (en) 2016-07-28 2019-06-05 Novartis AG Combination therapies of chimeric antigen receptors and pd-1 inhibitors
WO2018026819A2 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
KR20190057366A (en) 2016-10-07 2019-05-28 노파르티스 아게 Chimeric antigen receptor for the treatment of cancer
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018160731A1 (en) 2017-02-28 2018-09-07 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2019006007A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019018730A1 (en) 2017-07-20 2019-01-24 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
JP3720353B2 (en) * 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their preparation and use

Also Published As

Publication number Publication date
WO2002072635A2 (en) 2002-09-19
WO2002072635A3 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
AU6419701A (en) Electropancreatography
AU2001233918A1 (en) Pyridinylimidazoles
AU2002355245A1 (en) Novel compounds
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2002349297A1 (en) Statin-like compounds
AU2002360685A1 (en) Late-pcr
AU2002360508A1 (en) Substituted hydroxyethylamines
AU2002235430A1 (en) Money-transfer techniques
AU2001282743A1 (en) Electro-powder
AU2002359122A1 (en) Novel compounds
AU2002363250A1 (en) Pyrazole-amides and-sulfonamides
AU2002337489A1 (en) Inexsufflator
AU2002343498A1 (en) Angiopoietin-2 specific binding agents
AU2002333551A1 (en) Optoinjection methods
AU2002258644A1 (en) Novel nanoemulsions
AU2002311833A1 (en) Spiropyrazole compounds
AU2002343483A1 (en) Hydroxypropylamines
AU2002367404A1 (en) Redox-switchable materials
AU2002343482A1 (en) Prolyl-4-hydroxylases
AU2002303811A1 (en) Novel use
AU2001258224A1 (en) Wavepowermachine
AU2002358390A1 (en) Novel compounds
AU2002247826A1 (en) Specific binding members
AU2002317568A1 (en) Technical field
AU2002252240A1 (en) Novel biofungicide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase